PSMA‑Targeted Radioligand Therapy with the Radiopharmaceutical 177Lu‑PSMA‑617 in a Patient with Metastatic Castration‑Resistant Prostate Cancer
T. M. Geliashvili,
A. S. Krylov,
P. I. Bliganov,
B. I. Dolgushin,
A. I. Pronin,
A. S. Tyulyandina,
A. V. Parnas,
A. D. Ryzhkov,
A. V. Pavlova https://doi.org/10.37174/2587-7593-2023-6-1-88-96
Abstract
The expression of prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells is increased with tumor progression, which is the basis for a theranostic approach in the treatment of these patients. The PSMA ligand, labeled with the therapeutic radionuclide lutetium-177 (177Lu), delivers 177Lu beta particle radiation to PSMA-expressing prostate cancer cells. Currently, PSMA-targeted radioligand therapy with the radiopharmaceutical 177Lu-PSMA-617 is approved for the therapy of patients with metastatic castration-resistant prostate cancer (mCRPC). We present a clinical case of successful use of this method of treatment in our center in a patient with mCRPC, progressing after two lines of therapy — hormone therapy with new generation of androgen signal inhibitors (abiraterone, enzalutamide) and chemotherapy with docetaxel.
About the Authors
T. M. Geliashvili
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. S. Krylov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
P. I. Bliganov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
B. I. Dolgushin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. I. Pronin
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. S. Tyulyandina
N.N. Blokhin National Medical Research Center of Oncology; Department of Oncology of the Institute of N.V. Sklifosovsky Clinical Medicine Sechenov University
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478; 23, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. V. Parnas
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
A. D. Ryzhkov
N.N. Blokhin National Medical Research Center of Oncology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478; 2/1, build. 1, Barricadnaya str., Moscow, 125993
Competing Interests:
Not declared
A. V. Pavlova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
24, Kashirskoye Shosse, Moscow, 115478
Competing Interests:
Not declared
References
1. Hofman MS, Emmett L, Sandhu S, et al. 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 27;397(10276):797-804. DOI: 10.1016/S0140-6736(21)00237-3.
2. Sartor O, de Bono J, Chi KN, Fizazi K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-103. DOI: 10.1056/NEJMoa2107322.
Review
For citations:
Geliashvili T.M., Krylov A.S., Bliganov P.I., Dolgushin B.I., Pronin A.I., Tyulyandina A.S., Parnas A.V., Ryzhkov A.D., Pavlova A.V. PSMA‑Targeted Radioligand Therapy with the Radiopharmaceutical 177Lu‑PSMA‑617 in a Patient with Metastatic Castration‑Resistant Prostate Cancer. Journal of oncology: diagnostic radiology and radiotherapy. 2023;6(1):88-96. (In Russ.) https://doi.org/10.37174/2587-7593-2023-6-1-88-96
Views:
1409
Email this article 